Payment overview · 2025
General Payments
$924.08
53 reported records · 17 companies
Healthcare provider profile · identity verified
Jerod Walker, DO
Allopathic & Osteopathic Physicians|Family Medicine · WHEELERSBURG, OH · NPI 1952684227
Verified facts
What the public records show
CMS Open Payments records show Jerod Walker, DO received $924.08 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $225.84 | 24.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.35 | 15.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.87 | 9.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.86 | 7.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.41 | 6.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.76 | 6.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.30 | 5.9% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.10 | 5.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.82 | 5.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.72 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.43 | 2.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.73 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.20 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.29 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.25 | 1.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.71 | 1.5% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $2.44 | 0.3% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $921.64 | 50 |
| Education | $2.44 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $189.45 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.93 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $87.15 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $76.05 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.48 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.41 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.30 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.30 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $54.10 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.54 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.82 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $35.02 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $2.44 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 97 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
177 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 497 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 451 | 124 |
| Omeprazole | Omeprazole | 418 | 97 |
| Potassium Chloride | Potassium Chloride | 410 | 97 |
| Lisinopril | Lisinopril | 327 | 89 |
| Metformin Hcl | Metformin Hcl | 294 | 67 |
| Montelukast Sodium | Montelukast Sodium | 289 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 265 | 69 |
| Gabapentin | Gabapentin | 263 | 46 |
| Furosemide | Furosemide | 260 | 72 |
| Tizanidine Hcl | Tizanidine Hcl | 245 | 50 |
| Losartan Potassium | Losartan Potassium | 244 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 236 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 228 | 50 |
| Tramadol Hcl | Tramadol Hcl | 222 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 196 | 41 |
| Pregabalin | Pregabalin | 183 | 36 |
| Ozempic | Semaglutide | 177 | 27 |
| Lorazepam | Lorazepam | 173 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 44 |
| Simvastatin | Simvastatin | 166 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 43 |
| Famotidine | Famotidine | 129 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 24 |
| Trazodone Hcl | Trazodone Hcl | 121 | 29 |
| Carvedilol | Carvedilol | 111 | 34 |
| Ezetimibe | Ezetimibe | 111 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 24 |
| Donepezil Hcl | Donepezil Hcl | 105 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 23 |
| Eliquis | Apixaban | 97 | 24 |
| Meloxicam | Meloxicam | 97 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 94 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 21 |
| Jardiance | Empagliflozin | 90 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 37 |
| Sertraline Hcl | Sertraline Hcl | 85 | 26 |
| Glimepiride | Glimepiride | 81 | 16 |
| Ibuprofen | Ibuprofen | 79 | 27 |
| Allopurinol | Allopurinol | 75 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 17 |
| Topiramate | Topiramate | 73 | 18 |
| Prednisone | Prednisone | 72 | 55 |
| Metformin Hcl Er | Metformin Hcl | 67 | 21 |
| Spironolactone | Spironolactone | 67 | 18 |
| Bupropion Xl | Bupropion Hcl | 64 | 19 |
| Meclizine Hcl | Meclizine Hcl | 64 | 25 |
| Sucralfate | Sucralfate | 62 | 20 |
| Mounjaro | Tirzepatide | 61 | 12 |
| Buspirone Hcl | Buspirone Hcl | 60 | 19 |
| Clonazepam | Clonazepam | 56 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 56 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | 18 |
| Azithromycin | Azithromycin | 52 | 43 |
| Diazepam | Diazepam | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 15 |
| Celecoxib | Celecoxib | 49 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 36 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | 14 |
| Synthroid | Levothyroxine Sodium | 48 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 47 | 42 |
| Atenolol | Atenolol | 46 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 11 |
| Nystatin | Nystatin | 45 | 21 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 21 |
| Naproxen | Naproxen | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | 12 |
| Mupirocin | Mupirocin | 34 | 24 |
| Glipizide | Glipizide | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Cefdinir | Cefdinir | 21 | 16 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 14 |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Fentanyl | Fentanyl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Zaleplon | Zaleplon | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $924.08 · 53 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Filspari, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REXULTI, TRELEGY ELLIPTA, TRINTELLIX, VIBERZI, VRAYLAR, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error